Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.)

17 articles about Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.)

• After Failed Phase III, Auven to Terminate the KIACTA Program

  12/21/2016

• Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) Announces Positive Results From Pivotal Clinical Trial Of Seciera (OTX-101) In Dry Eye Disease

  11/13/2015

• Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) ' Kiacta™ Using Crowdsourcing And Telemonitoring

  9/19/2014

• Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Completion Of Enrollment In The Phase III Confirmatory Study of Kiacta™ For The Treatment Of AA Amyloidosis

  5/28/2014

• Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Engagement Of Financial Advisor To Explore Sale Of KIACTA™, An Experimental Drug In Phase 3 Development For The Treatment Of AA Amyloidosis

  5/7/2014

• Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Licence Agreement With Mount Sinai For KIACTATM In Sarcoidosis

  5/2/2014

• Celtic Therapeutics Rebrands as Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.)

  3/11/2013

• Celtic Therapeutics Announces the Appointment of New Partner

  10/29/2012

• Celtic Therapeutics Pledges $50 Million to Establish ADC Therapeutics, New Company Will Develop Antibody-Drug Conjugates

  3/26/2012

• Resolvyx Pharmaceuticals, Inc. and Celtic Therapeutics Enter Final Agreement in Ophthalmology

  1/10/2011

• Resolvyx Pharmaceuticals, Inc. and Celtic Therapeutics Ink Dry Eye Deal

  10/26/2010

• Celtic Therapeutics and Spirogen Limited Release: Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer

  9/15/2010

• Geller Biopharm Successfully Advises BELLUS Health in Its KIACTA(TM) Transaction With Celtic Therapeutics

  4/30/2010

• BELLUS Health and Celtic Therapeutics Enter Agreement Worth $20 Million for Drug candidate KIACTA(TM)

  4/30/2010

• PPD, Inc. to Invest $100 Million in Celtic Therapeutics

  10/28/2009

• Celtic Therapeutics Announces First Closing and Two Senior Appointments

  12/22/2008

• Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner

  12/18/2007